Wake up daily to our latest coverage of business done better, directly in your inbox.
Get your weekly dose of analysis on rising corporate activism.
The best of solutions journalism in the sustainability space, published monthly.
Select Newsletter
By signing up you agree to our privacy policy. You can opt out anytime.
Pharma company Novartis has supplied 300m antimalarial treatments without profit to treat children suffering from malaria.
The Swiss drugs giant has been delivering treatments since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries, using Coartem Dispersible which was developed by Novartis in collaboration with Medicines for Malaria Venture (MMV) specifically to meet the needs of children (weighing 5kg and above).
“This milestone underscores our long-standing commitment to the fight against malaria and to the children who are most at risk from the disease,” said Joseph Jimenez, CEO of Novartis. “We are proud of the part we have played in helping to reduce childhood deaths from malaria. And we continue to provide medicine at no profit to people who need it, contributing to the goal of a world free from the disease.”
Dr David Reddy, CEO of MMV, added: “The WHO World Malaria Report 2015 shows that we are making significant strides in reducing child mortality from malaria, and this is largely thanks to sustained international commitment and the availability of a range of innovative tools and solutions, including quality child-friendly medicines like Coartem® Dispersible.”
